Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): a randomised, double-blind, placebo-controlled, phase 3 trial

2021239 citationsJournal Articlebronze Open Access

Authors

Good health and well-being

Published in: The Lancet Diabetes & Endocrinology

Volume 9, Issue 9, pp. 586-594

Field-Weighted Citation Impact: 30.56